^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NFKB2 (Nuclear Factor Kappa B Subunit 2)

    i
    Other names: NFKB2, Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 2 (P49/P100), Lymphocyte Translocation Chromosome 10 Protein, Nuclear Factor NF-Kappa-B P100 Subunit, DNA-Binding Factor KBF2, Oncogene Lyt-10, P49/P100, LYT-10, NF-KB2, H2TF1, LYT10, Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 2, Nuclear Factor Of Kappa Light Chain Gene Enhancer In B Cells 2, Nuclear Factor NF-Kappa-B P52 Subunit, Nuclear Factor Kappa-B, Subunit 2, Transcription Factor NFKB2, NFKB, P52/P100 Subunit, CVID10
    1m
    Transcriptomic Profile of Pericontusional Tissue in Human Severe Traumatic Brain Injury. (PubMed, J Neurotrauma)
    More specifically, the CCL2-SPHK1 axis was validated at gene and protein expression levels in TBI. Further studies elucidating their role in angiogenesis and promotion of brain tissue repair, together with their potential applicability as therapeutic targets, are warranted.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • KLF4 (Kruppel-like factor 4) • CCL2 (Chemokine (C-C motif) ligand 2) • TGFB1 (Transforming Growth Factor Beta 1) • NFKB2 (Nuclear Factor Kappa B Subunit 2) • ATF3 (Activating Transcription Factor 3) • SPHK1 (Sphingosine Kinase 1)
    1m
    LE 8201: Leniolisib for immune dysregulation in CVID (2024-517725-93-00)
    P1/2, N=6, Active, not recruiting, Pharming Technologies B.V. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PTEN (Phosphatase and tensin homolog) • CD20 (Membrane Spanning 4-Domains A1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • IKZF1 (IKAROS Family Zinc Finger 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CARD11 (Caspase Recruitment Domain Family Member 11) • NFKB2 (Nuclear Factor Kappa B Subunit 2) • TNFRSF13C (TNF Receptor Superfamily Member 13C) • CD81 (CD81 Molecule) • SEC61A1 (SEC61 Translocon Subunit Alpha 1) • TNFRSF13B (TNF Receptor Superfamily Member 13B)
    1m
    Integrated transcriptomics and molecular docking identify hub genes and statin regulators in Helicobacter pylori-associated gastric mucosal pathogenesis. (PubMed, Front Cell Infect Microbiol)
    To explore potential therapeutic interventions, we performed small-molecule drug prediction and molecular docking for hub genes revealed: Simvastatin: Linked to CCL20, NFKBIA, and ICAM1. Atorvastatin: Associated with CDKN1A, ICAM1, and TNF. TPCA-1: Targeting JAK1. These findings provide a theoretical foundation for further investigation into the molecular mechanisms underlying H. pylori-related diseases.
    Journal
    |
    BRCA1 (Breast cancer 1, early onset) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • BIRC3 (Baculoviral IAP repeat containing 3) • JAK1 (Janus Kinase 1) • TNFAIP3 (TNF Alpha Induced Protein 3) • CCL20 (C-C Motif Chemokine Ligand 20) • ICAM1 (Intercellular adhesion molecule 1) • IRF1 (Interferon Regulatory Factor 1) • ITGAM (Integrin, alpha M) • SPI1 (Spi-1 Proto-Oncogene) • ETS1 (ETS Proto-Oncogene 1) • IL17A (Interleukin 17A) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NFKB2 (Nuclear Factor Kappa B Subunit 2) • NFKBIA (NFKB Inhibitor Alpha 2) • NFKBIE (NFKB Inhibitor Epsilon) • TRAF1 (TNF Receptor Associated Factor 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • E2F1 (E2F transcription factor 1) • EGR1 (Early Growth Response 1) • HSF1 (Heat Shock Transcription Factor 1) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit)
    |
    simvastatin • atorvastatin
    2ms
    Leniolisib for Immune Dysregulation in CVID (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Pharming Technologies B.V. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PTEN (Phosphatase and tensin homolog) • CD20 (Membrane Spanning 4-Domains A1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • IKZF1 (IKAROS Family Zinc Finger 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CARD11 (Caspase Recruitment Domain Family Member 11) • NFKB2 (Nuclear Factor Kappa B Subunit 2) • TNFRSF13C (TNF Receptor Superfamily Member 13C) • CD81 (CD81 Molecule) • SEC61A1 (SEC61 Translocon Subunit Alpha 1) • TNFRSF13B (TNF Receptor Superfamily Member 13B)
    2ms
    PLK1 stabilizes β-catenin to drive colorectal carcinogenesis through NFKB2-mediated transcriptional activation of USP2a and site-specific phosphorylation. (PubMed, Theranostics)
    Our study identified PLK1 as a key regulator of β-catenin signaling flexibility in CRC, coordinating kinase-dependent and transcriptional mechanisms to sustain pathway activation. The discovery of the PLK1-NFKB2-USP2a-β-catenin axis provides a novel therapeutic rationale for targeting PLK1 to selectively disrupt Wnt-driven tumorigenesis, potentially overcoming the toxicity limitations of conventional Wnt inhibitors.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • PLK1 (Polo Like Kinase 1) • NFKB2 (Nuclear Factor Kappa B Subunit 2)
    5ms
    Integrated multi-omic analysis unravels the characteristics of the metabolism-related intratumoral microbes and establishes a novel signature for predicting prognosis and therapeutic response in lung adenocarcinoma. (PubMed, Transl Cancer Res)
    Additionally, a microbial prognostic-predictive signature was established comprising Succinimonas, Collimonas, and Marichromatium, which also exhibited potential for indicating immunotherapeutic benefit and predicting drug sensitivity to cisplatin, cytarabine, pyrimethamine, olaparib, bicalutamide and vorinostat in LUAD treatment. This study identified intratumoral microbes associated with metabolism, revealed distinct subtypes and their roles in LUAD, and established a predictive signature for the prognosis and therapeutic responsiveness of LUAD.
    Journal • PARP Biomarker • IO biomarker
    |
    BCL3 (BCL3 Transcription Coactivator) • NFKB2 (Nuclear Factor Kappa B Subunit 2)
    |
    Lynparza (olaparib) • cisplatin • cytarabine • Zolinza (vorinostat) • bicalutamide
    5ms
    A comprehensive proteomic analysis uncovers novel molecular subtypes of gastric signet ring cell carcinoma: Identification of potential prognostic biomarkers and therapeutic targets. (PubMed, Genes Dis)
    Additionally, we identified four potential drug targets, including PFAS, EIF2S3, EIF6, and NFKB2. Molecular docking analysis suggested that neratinib, a clinically approved drug, could serve as a promising therapeutic agent for GSRCC, offering new avenues for clinical intervention.
    Journal
    |
    NFKB2 (Nuclear Factor Kappa B Subunit 2) • PRDX2 (Peroxiredoxin 2) • EIF6 (Eukaryotic Translation Initiation Factor 6)
    |
    Nerlynx (neratinib)
    6ms
    Spatial Transcriptional Dynamics of CD74⁺ B Cells in Tertiary Lymphoid Structures Drive Immune Evolution in Penile Squamous Cell Carcinoma. (PubMed, Adv Sci (Weinh))
    By engaging with naive T cells through HLA-DRA via ligand-receptor interactions, CD74⁺ B cells activate transcription factors, including NFKB1, NFKB2, NFATC1, NFATC2, FOS, and RUNX1, in naive T cells, thereby enhancing the immune response. Consequently, CD74⁺ B cells represent a compelling biomarker for and therapeutic target of PSCC, offering profound insights into the immunological mechanisms that drive PSCC progression and response to immunotherapy.
    Journal • IO biomarker
    |
    RUNX1 (RUNX Family Transcription Factor 1) • CD74 (CD74 Molecule) • HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha) • NFATC1 (Nuclear Factor Of Activated T Cells 1) • NFKB2 (Nuclear Factor Kappa B Subunit 2)
    6ms
    Developing and experimentally validating a glucocorticoid signaling-related gene signature to evaluate the prognosis and immunotherapeutic response in kidney renal clear cell carcinoma. (PubMed, PLoS One)
    In vivo experiments showed that NFKB2 knockdown inhibited tumor growth and the expansion of CD8+PDCD1+ T cells, effects that were reversible with corticosterone treatment (all P < 0.05). Collectively, a glucocorticoid signaling-related gene signature was developed and rigorously validated as a predictive tool for prognosis and immunotherapeutic response in KIRC, offering valuable insights for guiding personalized treatment strategies.
    Journal • Gene Signature • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • NFKB2 (Nuclear Factor Kappa B Subunit 2) • ACADM (Acyl-CoA Dehydrogenase Medium Chain)
    6ms
    Single-Cell Transcriptomic Analysis Highlights the Impact of NFKB2-Mediated MIF-CD44 Signaling Axis in Endometrioid Endometrial Cancer. (PubMed, Int J Womens Health)
    Our single-cell analysis details the EC TME landscape, revealing robust communication between M2_like2 macrophages and SOX9+LGR5- epithelial cells. We highlight a key mechanism where NFKB2 mediates MIF's pro-tumorigenic effects via the CD44 receptor, offering new insights into EC progression and potential therapeutic targets.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD74 (CD74 Molecule) • CDH1 (Cadherin 1) • SOX9 (SRY-Box Transcription Factor 9) • NFKB2 (Nuclear Factor Kappa B Subunit 2)
    7ms
    Gene Expression Insights into Cytarabine Resistance in Acute Myeloid Leukemia: The Role of Cytokines. (PubMed, Cancer Genomics Proteomics)
    This study identified key genes involved in cytokine dysregulation in cytarabine-resistant HL60 cells, providing potential targets for overcoming drug resistance in AML. These findings offer new avenues for the development of more effective therapies for relapsed or refractory AML patients.
    Journal
    |
    BCL3 (BCL3 Transcription Coactivator) • NFKB2 (Nuclear Factor Kappa B Subunit 2)
    |
    cytarabine